Cargando…
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. METHODS: We cond...
Autores principales: | Jackson, Lisa A., Anderson, Evan J., Rouphael, Nadine G., Roberts, Paul C., Makhene, Mamodikoe, Coler, Rhea N., McCullough, Michele P., Chappell, James D., Denison, Mark R., Stevens, Laura J., Pruijssers, Andrea J., McDermott, Adrian, Flach, Britta, Doria-Rose, Nicole A., Corbett, Kizzmekia S., Morabito, Kaitlyn M., O’Dell, Sijy, Schmidt, Stephen D., Swanson, Phillip A., Padilla, Marcelino, Mascola, John R., Neuzil, Kathleen M., Bennett, Hamilton, Sun, Wellington, Peters, Etza, Makowski, Mat, Albert, Jim, Cross, Kaitlyn, Buchanan, Wendy, Pikaart-Tautges, Rhonda, Ledgerwood, Julie E., Graham, Barney S., Beigel, John H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377258/ https://www.ncbi.nlm.nih.gov/pubmed/32663912 http://dx.doi.org/10.1056/NEJMoa2022483 |
Ejemplares similares
-
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020) -
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020) -
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis
por: Anderson, Evan, et al.
Publicado: (2022) -
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
por: Doria-Rose, Nicole, et al.
Publicado: (2021) -
Harnessing Novel Quantitative Pharmacology Approaches to Optimize the Treatment of Children With Tuberculosis
por: Seddon, James A., et al.
Publicado: (2016)